INTRODUCTION
Aluminium toxicity in uraemic patients arising from gastrointestinal absorption of aluminium has been reported to occur when a combination therapy consisting of aluminium hydroxide and Shohl's solution (a buffer of citric acid and sodium citrate) is utilized [1, 21. Since most aluminium compounds are insoluble at the pH of the intestine [3] , gastrointestinal ab of aluminium does not normally occur. r, aluminium forms complexes which are soluble at the pH of the intestine [4] . In addition, many aluminium complexes, includingcitrate, have been reported to exhibit enhanced partitioning from water into octanol [S] . The aluminium toxicity noted above has been attributed to the formation of soluble aluminium citrate complexes in the gastrointestinal tract [l, 21. This conclusion indicates the importance of aluminium speciation in the gastrointestinal absorption of aluminium.
The importance of aluminium speciation has also 425 been emphasized by the observation [6, 71 that aluminium citrate, but not aluminium lacta paracellular pathways in the intestinal and thereby enhances the absorption of aluminium. In order to investigate the effect of aluminium speciation on the aluminium absorption process, rat gut perfusion in vivo and partitioning experiments in vitro were performed. The perfusion e incorporated automated perfusate pH control, arterial cannulation for determination of the plasma aluminium level and determination of aluminium in both plasma and perfusate by electrothermal atomic absorption spectroscopy. The partitioning experiments measured the movement of aluminium from aqueous phases to ethyl acetate at pH values ranging from 2.5 to 8.0.
METHODS

Perfusi
ng the rat gut prepar [S] were d using male albino were fasted overnigh thetized with 50 mg of pentobarbital/kg. At the completion of the perfusion experiment, the animals were killed by exsanguination while anaesthetized. Perfusions were performed within a laminar flow hood in order to prevent contamination of samples. All glass-and plastic-ware was soaked overnight in 6 mol/l nitric acid, washed with distilled water and oven-dried. Perfusate solutions contained NaCl (140 mmol/l), KCl (4.56 mmol/l) and CaCl, (1.25 mmol/l), as well as AlCl, and sodium citrate, where indicated. In the first series of experiments, 67.5 mg of aluminium/l was added to the perfusate, and equimolar citrate was included in half the experi-.second series, the aluminium and citrate content of the perfusate was varied over several orders of magnitude from 6.75 to 675.0 mg of aluminium/l. Aluminium concentrations were chosen to bracket those expected to be found in the human intestinal lumen m dietary sources, 4-4Omg equivalent of Al, O, /day [9] , and the 500mg of equivalent A1203 in a normal dose of an aluminium hydroxide-containing phosphate binding agent [lo] . The aluminium was dispersed in 300ml of gastric fluid [ll] . Thus, the perfusate solutions for this study reflect the expected human intraluminal range of 6.75-675 mg of aluminium/l.
Twenty-five millilitres of perfusate were adjusted to the desired pH and transferred to a jacketed beaker maintained at 37°C. The pH of the perfusate was continuously monitored and maintained within 0.1 pH unit by a pH-stat titrator [PHM 62, TTT 60, ABU 12 (2.5ml) , TTA 60, REC 61; Radiometer, Copenhagen, Denmark]. The small intestine was perfused between the pylorus and the ileocaecal juncture by recirculation of the perfusate at an arbitrary rate of 7.5 ml/min.
Renal arteries were ligated in order to preclude renal elimination of absorbed aluminium. Blood samples (500 p1) were collected via a cannula inserted into the right carotid artery of heparinized (1000 units/kg) animals. Samples were centrifuged at 8000 rev./min, then plasma was diluted with an equal volume of solution containing 1.5 x lo-, mol/l Triton X-100 (Sigma Chemical Company, St Louis, MO, U.S.A.) and 1.4g of magnesium nitrate/l. Perfusate samples (1.5 ml) were centrifuged as above, then the supernatant solution was diluted with deionized, distilled water. Plasma and perfusate samples were analysed in triplicate for aluminium content by electrothermal atomic absorption spectroscopy (Atomic absorption spectrophotometer model 560, programmer model HGA 500 and graphite furnace model HGA 500, Perkin-Elmer, Norwalk, CN, U.S.A.) using a method adapted from the literature [12] . The adaptations included use of a pyrolytically coated graphite furnace tube, selection of a 2nm window slit and reading the sample absorbance without background correction. The furnace protocol employed is compared with the reference method in Table 1 . The sample drying temperature was reduced in order to prevent splattering, and the second char step was lengthened to reduce matrix effects. Additionally, a furnace cleaning step and a cool-down interval were added.
A reference aluminium solution (lo00 pg/ml; Fisher) was used to prepare fresh aluminium standards daily. A typical calibration curve was linear with a correlation coefficient (r2) of 0.99. The limit of detection was 6 pg/l. The analytical method was validated by standard addition of aluminium to plasma. The measured aluminium concentration was linearly related to the theoretical aluminium content, having an r2 value of 0.99. Repeated determinations showed the coefficient of variation to be less than 5% (n=9).
The soluble aluminium concentration of the perfusate was corrected for water inflow during the perfusion by use of a non-absorbable volume marker, Phenol Red. Perfusate samples were adjusted to pH 6.5 with phosphate buffer, and absorbance was determined spectrophotometrically at 560nm. The ratio of sample to initial Phenol Red concentrations was used to correct perfusate aluminium concentrations for volume changes. 
Height
Samples of intestinal mucosa after perfusion were collected in 3.3 mol/l neutral buffered formalin and examined by optical microscopy in order to observe gross morphological alterations that may have occurred as a result of perfusion conditions.
The model of partitioning in uitro was the ethyl acetate/water system. Each phase was presaturated with the opposite phase before use. Three aqueous aluminium phases were used: 0.1 mol/l A1C13 (2.7 g of aluminium/l); 0.1 mol/l AlCl, and 0.1 mol/l sodium citrate; and 0.1 mol/l AlCl, and 0.2mol/l sodium citrate. The pH was adjusted by the addition of either 1 mol/l HCl or 1 mol/l NaOH. A 20ml aliquot was transferred to a 125 ml glass-stoppered Erlenmeyer flask and an equal volume of ethyl acetate was added. The system was stirred at 800 rev./min by a Teflon-coated magnetic stir bar and maintained at 37°C by immersion in a water bath. An exposure time of 2.5 h was selected to approximate exposure to the absorptive regions of the gastrointestinal tract in uiuo. Samples were removed from the ethyl acetate phase and placed in acidwashed round bottom flasks. Samples were evaporated to dryness using a rotary evaporator. The residue was redissolved in lml of acetone and diluted to 10ml with deionized, distilled water. The aluminium content was determined in triplicate by electrothermal atomic absorption spectroscopy as described above. The pH of the aqueous phase was measured when the ethyl acetate phase was sampled. This pH, rather than the initial pH, was used to characterize the sample.
RESULTS
In order to examine the effect of pH on aluminium absorption, perfusate systems containing 67.5mg of A13+/l (2.5mmol/l AlCl,) and, in some cases, equimolar sodium citrate (2.5 mmol/l) were circulated through the rat gut in situ and maintained at pH4, 6 or 8. Fig. 1 shows the increase in plasma aluminium concentration in six rats after perfusion with a solution containing AlC13 at pH4. Blood samples taken at 0, 5 and 10min before perfusion began were used to establish the baseline plasma aluminium level of each rat. Two of the three perfusions with a solution containing only AlCl, (rats 1, 2 and 3) showed elevated plasma aluminium levels at 5min, but returned to baseline levels after 15min. The third remained at initial levels. In contrast, the three rats which were perfused with a solution equimolar in AlCl, and sodium citrate (rats 4, 5 and 6) exhibited increasing plasma aluminium levels over the 50 min perfusion period.
The soluble aluminium content of the perfusate was strongly affected by the presence of sodium citrate. As seen in Fig. 2 , perfusates containing only AlC1, exhibited a decreasing soluble aluminium content and approached zero over the course of the experiment. The soluble aluminium concentration of the perfusates which contained both AlC13 and sodium citrate remained at initial levels for the 60min perfusion period.
Figs. 3 and 4 present the increase in plasma aluminium concentration and the soluble aluminium concentration of the perfusate, respectively, when six rats were perfused at pH6. At this pH, which approximates the pH of the minimum solubility of Al(OH), [13] , there was no change in plasma aluminium level in the rats which were perfused with only AlCl, (rats 7, 8 and 9). Likewise, these perfusates exhibited virtually no soluble aluminium. The rats which were perfused with AlCl, and sodium citrate (rats 10, 11 and 12) all had elevated plasma aluminium levels over the 90 min experiment. These perfusates exhibited high concentrations of soluble aluminium.
Perfusion at pH8 with AlCl, resulted in no significant increase in plasma aluminium levels (Fig.  5, rats 13, 14 and 15 ), but an increase was observed when the perfusate contained AlCl, and sodium citrate (Fig. 5, rats 16, 17 and 19 ). The elevated aluminium plasma levels were again associated with a high level of soluble aluminium in the perfusate (Fig. 6) , whereas no increase in the plasma aluminium level was seen when the soluble aluminium concentration of the perfusate approached zero.
Microscopic examination of the intestinal membrane for gross physical damage revealed mild morphological changes at pH 4. The villi appeared short or clubbed, and lymph vessels at the base of the villi were distended as a result of oedema. However, the epithelial barrier was intact. In contrast, no evidence of irritation and no obvious morphological changes were identified at pH 6 or 8.
The concentration dependence of aluminium absorption was investigated at pH 4 using perfusates containing equimolar concentrations of AICl, and sodium citrate. As seen in Table 2 , a 100-fold increase in the soluble aluminium concentration of the perfusate resulted in a proportional increase in the plasma aluminium concentration.
The partitioning behaviour of the aluminium citrate complex in uitro was investigated as well. A1C13 and AIC1,-sodium citrate solutions at 1: 1 and 1:2 molar ratios of aluminium to citrate were adjusted to the desired pH and exposed to an equal volume of ethyl acetate. Fig. 7 represents the aluminium concentration in the ethyl acetate phase. Parti-tioning of unchelated aluminium species resulted in low levels of aluminium in the ethyl acetate phase. Maximum partitioning occurred at pH 2.5. As the data in Fig. 7 indicate, the 1: 1 aluminium citrate complex partitioned into ethyl acetate to a significantly greater extent than did unchelated aluminium species (P < 0.05). Not only was the partitioning enhanced compared with unchelated aluminium species, but chelation also resulted in a much higher level of partitioning up to pH 8. The chelated aluminium partitioned to levels between 20 and 30pg/l over the pH range 3.0-6.0. In contrast, unchelated aluminium species exhibited a maximum partitioning of 15pg/l at pH2.5 and exhibited virtually no partitioning above pH 5.0.
Partitioning from an aluminium citrate solution that contained a 1:2 molar ratio of aluminium to citrate, shown in Fig. 7 , resulted in aluminium concentrations in the ethyl acetate phase that were virtually identical with those found with an aluminium to citrate ratio of 1:l. Thus, an excess of citrate did not affect the level of partitioning into the organic phase.
DlSCU SSlO N
In order to evaluate the means by which aluminium species are absorbed, a series of perfusions under controlled conditions were performed. Perfusate conditions were selected to examine the effect of speciation of aluminium at various pH conditions in the presence and absence of citrate anion. Additionally, a series of experiments was conducted in which the concentration of aluminium and citrate present in the perfusate was varied in order to examine-the absorption mechanism.
In the first series, all of the perfusates initially contained 67.5 mg of aluminium/l. These experiments determined the concentration of aluminium in solution in the perfusate during circulation. Thus, the disappearance of soluble aluminium species may be attributed to either absorption, precipitation or binding to the gut wall. Aluminium solubility is at a minimum at pH 6.5 with solubilities of 67.5 mg/l achieved below pH 4 or above pH 10 [13]. Thus, an Al(OH), precipitate forms when the pH of AlCl, solutions containing 67.5 mg of A13 +/l is between pH4 and 10. Virtually no soluble aluminium was present in AlCl, perfusates circulated at pH4, 6 or 8 (Figs. 2, 4 and 6) and no increase in plasma aluminium levels (Figs. 1, 3 and 5) resulted from perfusion of these solutions.
The presence of citrate anion in the perfusate resulted in high soluble aluminium concentrations at all pH conditions (Figs. 2, 4 and 6) . Citrate is known to associate with aluminium cations to form a series of complexes which are soluble over the physiological pH range, i.e. pH2 for gastric fluid to pH7.4 for blood. Elevated plasma aluminium concentrations obtained at pH4, 6 and 8 (Figs. 1, 3 and 5) are associated with high levels of soluble alumi- nium in the sodium citrate-containing perfusate, although the aluminium species present in solution differ with the solution pH [14] .
Chelation of aluminium by citrate results in the equilibrium formation of complex species that may be cationic, neutral or anionic, depending on the pH, in addition to free citrate and aluminium species. The distribution of these species as a function of pH has been calculated by Motekaitis & Martel [14] . Fig. 8 shows that the protonated aluminium citrate complex (AlHCit) exists at low pH, but falls to baseline levels at approximately pH4.0. The neutral complex (AlCit) reaches a maximum at approximately pH 3.0. Above pH 4.0, the anionic complex (AlH -,Cit) predominates. Citric acid (H,L) is present below pH3. The monovalent dihydrogen citrate anion (H,L) is present up to pH 4.0. Negligible quantities of divalent hydrogen citrate anion (HL) are present in the system. The trivalent citrate anion (Cit -, ) becomes the predominant citrate-containing species above pH 8. Comparison of the partitioning behaviour of the aluminium citrate system shown in Fig. 7 with the diagram of aluminium species (Fig. 8) suggests that partitioning of the anionic aluminium citrate complex is responsible for extending the partitioning range to pH8. It is important to note that the aluminium citrate complex species are not only soluble in water, but they also show enhanced partitioning from water into an organic phase.
The results in Fig. 7 have important implications in uiuo as the chelation of aluminium by citrate leads to significantly elevated partitioning in the pH range of the intestine. The ability to partition under pH conditions similar to those found in the intestine may be an additional property of aluminium citrate complexes which contributes to enhanced absorption of aluminium citrate species relative to unchelated aluminium species in uiuo.
The direct relationship between the soluble aluminium concentration of the perfusate over the concentration range 6.75-675 mg of A13+/l and the increase in the plasma aluminium level seen in Table 2 suggest that a concentration-dependent mechanism, such as passive diffusion, is responsible for the absorption of citrate-solubilized aluminium.
These perfusions were carried out at three pH values in order to examine potential differences in absorption due to speciation of aluminium citrate complexes at the various pH levels. That no significant differences were observed refutes the notion that the neutral aluminium citrate complex, which exists below pH5, is uniquely important in aluminium absorption [4]. At pH 4, both the neutral and anionic aluminium citrate complex are present to contribute to aluminium absorption. At pH 6, absorption must be due to the anionic aluminium citrate complex, as it is the only aluminium species present (Fig. 8) . The anionic aluminium citrate complex and the aluminate anion are the only soluble aluminium species present at pH 8. Thus, the major requirement for aluminium absorption appears to be the presence of a soluble aluminium species.
At all three pH values the presence of citrate resulted in observed increases in plasma aluminium levels, and the observed increases were proportional to the aluminium citrate concentration in the perfusate. These results are consistent with recent mechanistic studies [6, 71, in that the aluminium species is required to be in solution and absorption is by a passive mechanism. These studies [6, 71 have concluded that citrate opens paracellular pathways, resulting in a passive influx of soluble aluminium species.
Thus, this study has demonstrated that soluble aluminium species are a prerequisite for gastrointestinal absorption of aluminium. Although the citrate anion is particularly relevant because of its use in treating acidosis in uraemic patients, other ligands also extend the pH range of aluminium solubility [3] and their effect on aluminium absorption should be determined.
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